Nova Eye Medical (ASX:EYE) EPS (Basic): A$-0.03 (TTM As of Dec. 2025)


ASX:EYE Nova Eye Medical Ltd ASX:EYE
55 GF Score
Price A$0.10
GF Value A$0.18
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Nova Eye Medical EPS (Basic)?

Nova Eye Medical ASX:EYE +2.50% 55 EPS (Basic) is A$-0.03 as of Dec. 2025. GuruFocus rates ASX:EYE with a GF Score™ of 55/100 and a GF Value™ of A$0.18 (Possible Value Trap). The stock has 4 warning signs investors should review.

Nova Eye Medical's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was A$-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.03.

Nova Eye Medical's EPS (Diluted) for the six months ended in Dec. 2025 was A$-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.03.

Nova Eye Medical's EPS without NRI for the six months ended in Dec. 2025 was A$-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.03.

During the past 3 years, the average EPS without NRI Growth Rate was 9.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Nova Eye Medical's highest 3-Year average EPS without NRI Growth Rate was 75.00% per year. The lowest was -115.40% per year. And the median was 6.50% per year.

Nova Eye Medical  (ASX:EYE) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Nova Eye Medical EPS (Basic) Related Terms

Nova Eye Medical EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Nova Eye Medical's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nova Eye Medical EPS (Basic) Chart

Nova Eye Medical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.05 -0.10 -0.04 -0.04

Nova Eye Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.01 -0.02 -0.01 -0.01
ASX:EYE
55GF Score
Nova Eye Medical Ltd ASX:EYE
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nova Eye Medical EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Nova Eye Medical's Basic EPS for the fiscal year that ended in Jun. 2025 is calculated as

Basic EPS (A: Jun. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-9.059-0)/247.334
=-0.04

Nova Eye Medical's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-3.365-0)/284.833
=-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of A$-0.03 mean?
Nova Eye Medical (ASX:EYE) has a EPS (Basic) of A$-0.03 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Nova Eye Medical and its competitors.
Is Nova Eye Medical's EPS (Basic) too high?
Nova Eye Medical's current EPS (Basic) is A$-0.03. Overall, Nova Eye Medical has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nova Eye Medical's EPS (Basic) compare to ABT and SYK?
Nova Eye Medical's EPS (Basic) of A$-0.03 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Devices & Instruments company?
A good EPS (Basic) depends on the Medical Devices & Instruments industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Nova Eye Medical and its competitors. Nova Eye Medical's current EPS (Basic) is A$-0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Eye Medical stock overvalued right now?
Based on GuruFocus' analysis, Nova Eye Medical (ASX:EYE) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.18, compared to a current price of A$0.10 — trading 43.1% below its estimated fair value. The current EPS (Basic) is A$-0.03. Nova Eye Medical's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Nova Eye Medical (ASX:EYE), the current EPS (Basic) is A$-0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nova Eye Medical (ASX:EYE) Overvalued in 2026?

Based on GuruFocus' analysis, Nova Eye Medical stock appears to be undervalued. The current stock price of A$0.10 is trading 43.1% below its estimated GF Value™ of A$0.18. GuruFocus considers Nova Eye Medical to be Possible Value Trap.

Key valuation signals for ASX:EYE:

  • EPS (Basic): A$-0.03
  • GF Value™: A$0.18 vs. price of A$0.10 (43.1% below fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the ASX:EYE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nova Eye Medical Business Description

Address 107 Rundle Street, Kent Town, Adelaide, SA, AUS, 5067
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.
55GF Score

Get the complete analysis for ASX:EYE

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.10
Price
A$0.18
GF Value